Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...
Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...
These updates will also be presented at the American Society of Gene and Cell Therapy and Muscular Dystrophy Association 2024 Breakthroughs ... including RGX-202 for the treatment of Duchenne, ...
Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).
The global Duchenne muscular dystrophy (DMD) therapeutics market is set to grow by $4.4 billion from 2024 to 2028, with a ...
WOOD Grand Rapids on MSN10d
Photos: GR .1K for Duchenne muscular dystrophyPeople hit the road for a short race Saturday to support research into Duchenne muscular dystrophy. The GR .1K was held ...
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...
Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company ...
The company’s focus has shifted toward upcoming data readouts for sevasemten in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), following positive results for EDG-7500 in ...
According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback